Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 198
Filter
1.
Brain Stimul ; 15(1): 63-72, 2022.
Article in English | MEDLINE | ID: mdl-34767967

ABSTRACT

BACKGROUND: The efficacy of repetitive transcranial magnetic stimulation (rTMS) for depression may vary depending on the subregion stimulated within the dorsolateral prefrontal cortex (DLPFC). Clinical TMS typically uses scalp-based landmarks for DLPFC targeting, rather than individualized MRI guidance. OBJECTIVE: In rTMS patients, determine the brain systems targeted by multiple DLPFC stimulation rules by computing several surrogate measures: underlying brain targets labeled with connectivity-based atlases, subgenual cingulate anticorrelation strength, and functionally connected networks. METHODS: Forty-nine patients in a randomized controlled trial of rTMS therapy for treatment resistant major depression underwent structural and functional MRI. DLPFC rules were applied virtually using MR-image guidance. Underlying cortical regions were labeled, and connectivity with the subgenual cingulate and whole-brain computed. RESULTS: Scalp-targeting rules applied post hoc to these MRIs that adjusted for head size, including Beam F3, were comparably precise, successful in directly targeting classical DLPFC and frontal networks, and anticorrelated with the subgenual cingulate. In contrast, all rules involving fixed distances introduced variability in regions and networks targeted. The 5 cm rule targeted a transitional DLPFC region with a different connectivity profile from the adjusted rules. Seed-based connectivity analyses identified multiple regions, such as posterior cingulate and inferior parietal lobe, that warrant further study in order to understand their potential contribution to clinical response. CONCLUSION: EEG-based rules consistently targeted DLPFC brain regions with resting-state fMRI features known to be associated with depression response. These results provide a bridge from lab to clinic by enabling clinicians to relate scalp-targeting rules to functionally connected brain systems.


Subject(s)
Depressive Disorder, Treatment-Resistant , Transcranial Magnetic Stimulation , Depression/diagnostic imaging , Depression/therapy , Depressive Disorder, Treatment-Resistant/diagnostic imaging , Depressive Disorder, Treatment-Resistant/therapy , Humans , Magnetic Resonance Imaging , Prefrontal Cortex/physiology , Transcranial Magnetic Stimulation/methods
2.
Brain Stimul ; 14(3): 703-709, 2021.
Article in English | MEDLINE | ID: mdl-33866020

ABSTRACT

BACKGROUND: Precise targeting of brain functional networks is believed critical for treatment efficacy of rTMS (repetitive pulse transcranial magnetic stimulation) in treatment resistant major depression. OBJECTIVE: To use imaging data from a "failed" clinical trial of rTMS in Veterans to test whether treatment response was associated with rTMS coil location in active but not sham stimulation, and compare fMRI functional connectivity between those stimulation locations. METHODS: An imaging substudy of 49 Veterans (mean age, 56 years; range, 27-78 years; 39 male) from a randomized, sham-controlled, double-blinded clinical trial of rTMS treatment, grouping participants by clinical response, followed by group comparisons of treatment locations identified by individualized fiducial markers on structural MRI and resting state fMRI derived networks. RESULTS: The average stimulation location for responders versus nonresponders differed in the active but not in the sham condition (P = .02). The average responder location derived from the active condition showed significant negative functional connectivity with the subgenual cingulate (P < .001) while the nonresponder location did not (P = .17), a finding replicated in independent cohorts of 84 depressed and 35 neurotypical participants. The responder and nonresponder stimulation locations evoked different seed based networks (FDR corrected clusters, all P < .03), revealing additional brain regions related to rTMS treatment outcome. CONCLUSION: These results provide evidence from a randomized controlled trial that clinical response to rTMS is related to accuracy in targeting the region within DLPFC that is negatively correlated with subgenual cingulate. These results support the validity of a neuro-functionally informed rTMS therapy target in Veterans.


Subject(s)
Depressive Disorder, Treatment-Resistant , Transcranial Magnetic Stimulation , Brain/diagnostic imaging , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Prefrontal Cortex , Treatment Outcome
3.
Int Psychogeriatr ; 25(4): 607-16, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23237099

ABSTRACT

BACKGROUND: Cognitive training has been shown to improve memory in older adults; however, little is known about which individuals benefit from or respond best to training in the long term. Identification of responders' characteristics would help providers match cognitive interventions to individuals to improve their effectiveness. Signal detection methods may prove more informative than more commonly used analytic methods. The goal of the current study is to identify baseline characteristics of long-term treatment responders and of those able to maintain their initial benefit from cognitive training. METHODS: Participants were 120 non-demented, community-dwelling older adults who had participated in a cognitive training intervention. Tested predictors included both demographic and neurocognitive variables. Primary outcome variables were performance on measures of memory at one-year follow-up. RESULTS: Results of the signal detection analysis indicated that different neurocognitive performances predicted long-term effects of memory training and maintenance of initial treatment response according to different types of to-be-remembered material. Higher baseline scores on tests of associative memory, delayed verbal memory, attention, episodic memory, and younger age were found predictive of long-term response one year later. Higher associative memory scores and lower initial gains at the end of treatment (week 14) predicted successful maintenance of training gains at week 52. CONCLUSIONS: To derive long-term benefit from particular cognitive training programs, it appears necessary for older adults to have specific neurocognitive profiles. Further, inclusion of booster sessions to cognitive training programs may assist in maintenance of initial treatment gains.


Subject(s)
Cognition/physiology , Cognitive Behavioral Therapy/methods , Long-Term Care/methods , Memory , Signal Detection, Psychological , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Male , Mental Recall , Middle Aged , Neuropsychological Tests , ROC Curve , Treatment Outcome
4.
Eur J Neurol ; 19(6): 918-23, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22340757

ABSTRACT

BACKGROUND: Periodic leg movements in sleep (PLMS) are non-epileptiform, repetitive movements of the lower limbs that have been associated with apparent dopamine deficiency. We hypothesized that elderly patients with a disease characterized primarily by dopamine depletion (Parkinsonism) would have higher rates of PLMS than age-matched controls or a different neurodegenerative condition not primarily involving a hypodopaminergic state, Alzheimer's disease (AD). METHODS: We compared rates of PLMS derived from in-laboratory overnight polysomnography in patients with Parkinsonism (n = 79), AD (n = 28), and non-neurologically impaired, community-based controls (n = 187). RESULTS: Patients with Parkinsonism not receiving levodopa had significantly higher rates of PLMS than did patients with Parkinsonism receiving levodopa as well as higher rates than seen in AD and controls. Other medications did not appear to exert the pronounced effect of levodopa on PLMS in this Parkinsonian patient population. The symptom of leg kicking was reported more frequently in Parkinsonism and was associated with higher rates of PLMS. Caregiver reported leg kicking was unrelated to PLMS in AD. CONCLUSIONS: Results are broadly compatible with a dopaminergic hypothesis for PLMS in Parkinsonism. The clinical significance of the negative findings in patients with AD requires further investigation.


Subject(s)
Alzheimer Disease/complications , Parkinsonian Disorders/complications , Restless Legs Syndrome/diagnosis , Restless Legs Syndrome/etiology , Aged , Electromyography , Female , Humans , Lower Extremity/physiopathology , Male , Middle Aged , Movement/physiology , Polysomnography , Psychiatric Status Rating Scales , Residence Characteristics , Severity of Illness Index
5.
J Alzheimers Dis ; 26 Suppl 3: 331-6, 2011.
Article in English | MEDLINE | ID: mdl-21971472

ABSTRACT

OBJECTIVES: Magnetic Resonance Spectroscopy (MRS) may provide a precise and reliable assessment of the extent and severity of neural tissue loss caused by various diseases. In particular, the N-Acetyl Aspartate (NAA) and Creatine (Cr) ratio has been found to be an indicator of the degree of neuronal loss in Alzheimer's disease (AD). Memantine is thought to benefit the AD brain by stabilizing the NMDA receptors on neurons in turn reducing excitotoxicity. Despite its effectiveness in treating moderate to severe AD, memantine has not had similar success in the treatment of mildly demented AD patients. The objective of this study was to test whether memantine would slow or prevent the loss of neurons in mild to moderate AD patients. METHODS: A double-blind placebo-controlled study was designed to measure the effect of a year-long course of memantine in patients with a probable AD diagnosis with mild to moderate dementia. The primary outcome measure was stipulated to be change in MRS NAA/Cr ratio in inferior parietal cortex in memantine relative to the placebo treatment condition. The secondary outcome measures were changes in cognitive and function scale scores. RESULTS: This pilot study failed to demonstrate a benefit of memantine on the primary outcome measure, the inferior parietal NAA/Cr ratio, or the secondary outcome measures. CONCLUSIONS: More studies are needed to determine the effect of memantine on regions of the brain significantly affected by AD pathology.


Subject(s)
Alzheimer Disease , Excitatory Amino Acid Antagonists/therapeutic use , Magnetic Resonance Spectroscopy , Memantine/therapeutic use , Aged , Aged, 80 and over , Alzheimer Disease/diagnosis , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Aspartic Acid/analogs & derivatives , Aspartic Acid/metabolism , Brain Mapping , Creatine/metabolism , Double-Blind Method , Female , Humans , Longitudinal Studies , Male , Neuropsychological Tests , Pilot Projects
6.
Behav Genet ; 41(5): 700-8, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21193954

ABSTRACT

The polymorphic variation in the val158met position of the catechol-O-methyltransferase (COMT) gene is associated with differences in executive performance, processing speed, and attention. The purpose of this study is: (1) replicate previous COMT val158met findings on cognitive performance; (2) determine whether COMT val158met effects extend to a real-world task, aircraft navigation performance in a flight simulator; and (3) determine if aviation expertise moderates any effect of COMT val158met status on flight simulator performance. One hundred seventy two pilots aged 41-69 years, who varied in level of aviation training and experience, completed flight simulator, cognitive, and genetic assessments. Results indicate that although no COMT effect was found for an overall measure of flight performance, a positive effect of the met allele was detected for two aspects of cognitive ability: executive functioning and working memory performance. Pilots with the met/met genotype benefited more from increased levels of expertise than other participants on a traffic avoidance measure, which is a component of flight simulator performance. These preliminary results indicate that COMT val158met polymorphic variation can affect a real-world task.


Subject(s)
Aviation/methods , Catechol O-Methyltransferase/genetics , Cognition/physiology , Polymorphism, Genetic , Adult , Age Factors , Aged , Aircraft , Cognition Disorders/genetics , Computer Simulation , Female , Humans , Male , Methionine/genetics , Middle Aged , Neuropsychological Tests , Valine/genetics
7.
Transl Psychiatry ; 1: e51, 2011 Oct 25.
Article in English | MEDLINE | ID: mdl-22833197

ABSTRACT

Numerous studies have indicated a link between the presence of polymorphism in brain-derived neurotrophic factor (BDNF) and cognitive and affective disorders. However, only a few have studied these effects longitudinally along with structural changes in the brain. This study was carried out to investigate whether valine-to-methionine substitution at position 66 (val66met) of pro-BDNF could be linked to alterations in the rate of decline in skilled task performance and structural changes in hippocampal volume. Participants consisted of 144 healthy Caucasian pilots (aged 40-69 years) who completed a minimum of 3 consecutive annual visits. Standardized flight simulator score (SFSS) was measured as a reliable and quantifiable indicator for skilled task performance. In addition, a subset of these individuals was assessed for hippocampal volume alterations using magnetic resonance imaging. We found that val66met substitution in BDNF correlated longitudinally with the rate of decline in SFSS. Structurally, age-dependent hippocampal volume changes were also significantly altered by this substitution. Our study suggests that val66met polymorphism in BDNF can be linked to the rate of decline in skilled task performance. Furthermore, this polymorphism could be used as a predictor of the effects of age on the structure of the hippocampus in healthy individuals. Such results have implications for understanding possible disabilities in older adults performing skilled tasks who are at a higher risk for cognitive and affective disorders.Translational Psychiatry (2011) 1, e51; doi:10.1038/tp.2011.47; published online 25 October 2011.


Subject(s)
Aerospace Medicine , Brain-Derived Neurotrophic Factor/genetics , Hippocampus/anatomy & histology , Hippocampus/physiopathology , Motor Skills/physiology , Polymorphism, Genetic/genetics , Psychomotor Performance/physiology , Adult , Aged , Amino Acid Substitution/genetics , Cross-Sectional Studies , Female , Hippocampus/physiology , Humans , Longitudinal Studies , Male , Middle Aged , Predictive Value of Tests , Psychomotor Performance/classification , United States , Workforce
8.
J Nutr Health Aging ; 14(3): 203-6, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20191254

ABSTRACT

Sleep and wake in Alzheimer's disease (AD) are often fragmented as manifested by bouts of wakefulness at night and napping during the day. Management of sleep disturbances in AD is important because of their negative impact on both patients and caregivers. Pharmacological treatments, mainly sedative-hypnotics and antipsychotics, are often used but can be associated with significant adverse effects. Non-pharmacological treatments represent a beneficial alternative approach to the management of sleep disturbances in AD since they are associated with fewer adverse effects and their efficacy can be sustained after treatment has been completed. The aim of this article is to review non-pharmacological treatments, such as sleep hygiene, sleep restriction therapy (SRT), cognitive behavioral therapy (CBT), light therapy, and continuous positive airway pressure (CPAP), for the management of sleep/wake disturbances in AD.


Subject(s)
Alzheimer Disease/complications , Sleep Wake Disorders/therapy , Actigraphy , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Cognitive Behavioral Therapy , Continuous Positive Airway Pressure , Humans , Hygiene , Hypnotics and Sedatives/therapeutic use , Melatonin/therapeutic use , Phototherapy , Sleep Wake Disorders/complications , Sleep Wake Disorders/diagnosis
9.
Proc Natl Acad Sci U S A ; 106(29): 12145-50, 2009 Jul 21.
Article in English | MEDLINE | ID: mdl-19581601

ABSTRACT

A number of distinct beta-amyloid (Abeta) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural Abeta-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic Abeta and amyloidogenic non-Abeta species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21-89 years. Antibody reactivity was most prominent against oligomeric assemblies of Abeta and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of Abeta1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant Abeta, ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from Abeta toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with Abeta the monkeys developed high titers not only against Abeta peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of Abeta antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.


Subject(s)
Aging/immunology , Alzheimer Disease/immunology , Amyloid beta-Peptides/chemistry , Amyloid beta-Peptides/immunology , Antibodies/immunology , Neuroprotective Agents/immunology , Peptides/immunology , Aging/drug effects , Alzheimer Disease/blood , Alzheimer Disease/complications , Alzheimer Disease/pathology , Amyloid beta-Peptides/toxicity , Animals , Antibodies/blood , Antibodies/cerebrospinal fluid , Cytoprotection/drug effects , Dementia/complications , Dementia/immunology , Disease Progression , Genes, Dominant , Immunization , Immunoglobulin G/blood , Mice , Molecular Weight , Neurons/cytology , Neurons/drug effects , Peptides/chemistry , Primates/immunology , Protein Processing, Post-Translational/drug effects , Protein Structure, Quaternary
11.
J Geriatr Psychiatry Neurol ; 19(1): 32-5, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16449758

ABSTRACT

The current study used Department of Veteran's Affairs (VA) clinical records, State of California pesticide application records, spatial maps of distribution of Parkinson's disease patients, and pesticide applications to determine if there was evidence for "blow-in" of pesticides as a factor in explaining the prevalence of Central Valley Parkinson's disease. The results did not support the hypothesis of increasing prevalence of Parkinsonism attributable to wind drift.


Subject(s)
Agriculture , Air Pollutants/toxicity , Parkinson Disease/epidemiology , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/epidemiology , Pesticides/toxicity , Topography, Medical , Wind , Air Pollutants/analysis , California , Causality , Cross-Sectional Studies , Humans , Parkinson Disease/diagnosis , Parkinsonian Disorders/diagnosis , Pesticides/analysis , Risk , Statistics as Topic
12.
Neurology ; 65(4): 642-4, 2005 Aug 23.
Article in English | MEDLINE | ID: mdl-16116137

ABSTRACT

The authors investigated the relationship between obstructive sleep apnea/hypopnea (OSAH) and cognition in 36 older adults, 18 APOE epsilon4 carriers, and 18 non-carriers. Greater numbers of respiratory events negatively impacted memory function in epsilon4 carriers only. This is the first study to provide preliminary evidence for a negative interaction of APOE epsilon4 and OSAH on memory in older adults, which may have important implications for treating cognitive decline and delaying dementia onset.


Subject(s)
Apolipoproteins E/genetics , Genetic Predisposition to Disease/genetics , Heterozygote , Memory Disorders/genetics , Sleep Apnea Syndromes/complications , Sleep Apnea Syndromes/genetics , Aged , Apolipoprotein E4 , Brain/metabolism , Brain/physiopathology , Cognition Disorders/genetics , Cognition Disorders/physiopathology , DNA Mutational Analysis , Disease Progression , Female , Genetic Testing , Genetic Variation/genetics , Humans , Male , Memory Disorders/physiopathology , Memory Disorders/psychology , Middle Aged , Neuropsychological Tests , Oxidative Stress/genetics , Sleep Apnea Syndromes/physiopathology , Sleep Stages/genetics
13.
J Geriatr Psychiatry Neurol ; 17(1): 36-8, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15018696

ABSTRACT

The purpose of this study was to assess whether pharmacy database information from US Department of Veterans Affairs (VA) medical centers could be used to screen for areas of higher Parkinson's disease prevalence in patients exposed to pesticides. The authors used pharmacy data sets and compared the use of antiparkinsonian medications at 2 VA medical centers in California: one in Palo Alto, near the ocean, and one in Fresno, downwind from extensively farmed parts of the Central Valley. They found that patients at Fresno had higher odds ratios (1.5-1.8) for the use of Parkinson's disease medications than patients at Palo Alto. These data are consistent with the observations of prior epidemiologic studies and suggest that VA pharmacy databases can prioritize locations for further epidemiologic research. However, a thorough exploration of alternative explanations is needed to reach definitive conclusions regarding the findings suggested by this method.


Subject(s)
Antiparkinson Agents/therapeutic use , Databases as Topic/statistics & numerical data , Environmental Exposure/adverse effects , Hospital Information Systems/statistics & numerical data , Mass Screening/statistics & numerical data , Parkinson Disease, Secondary/chemically induced , Pesticides/toxicity , Pharmacy Service, Hospital/statistics & numerical data , Veterans/statistics & numerical data , California/epidemiology , Environmental Exposure/statistics & numerical data , Humans , Odds Ratio , Parkinson Disease, Secondary/drug therapy , Parkinson Disease, Secondary/epidemiology , Risk Assessment/statistics & numerical data
14.
Neurology ; 59(1): 123-5, 2002 Jul 09.
Article in English | MEDLINE | ID: mdl-12105320

ABSTRACT

We report a randomized, double-blind, parallel group, placebo-controlled study to test the effects of the acetylcholinesterase inhibitor, donepezil (5 mg/d for 30 days), on aircraft pilot performance in 18 licensed pilots with mean age of 52 years. After 30 days of treatment, the donepezil group showed greater ability to retain the capacity to perform a set of complex simulator tasks than the placebo group, p < 0.05. Donepezil appears to have beneficial effects on retention of training on complex aviation tasks in nondemented older adults.


Subject(s)
Cholinesterase Inhibitors/administration & dosage , Indans/administration & dosage , Motor Skills/drug effects , Piperidines/administration & dosage , Adult , Aged , Aging , Aviation , Donepezil , Double-Blind Method , Humans , Middle Aged , Psychomotor Performance/drug effects
15.
J Stud Alcohol ; 62(4): 422-33, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11523532

ABSTRACT

OBJECTIVE: Previous studies investigating the influence of the menstrual cycle on cognitive functioning of women after alcohol ingestion have obtained inconsistent results. The present study tested the hypothesis that flight simulator performance during acute alcohol intoxication and 8 hours after drinking differs between the menstrual and the luteal phase of the menstrual cycle. METHOD: White female pilots (N = 24) were tested during the menstrual and the luteal phases of their menstrual cycles. On each test day they performed a baseline simulator flight, consumed 0.67 g/kg ethanol, and performed an acute-intoxication and an 8-hour-carryover simulator flight. RESULTS: Subjects reached highly significant increases in estradiol (E2) as well as progesterone (P) levels during the luteal test day. Yet, there were no significant differences in overall flight performance after alcohol ingestion between the menstrual and luteal phases during acute intoxication or at 8-hour carryover. We found no correlations between E, or P levels and overall flight performance. However, there was a statistically significant Phase x Order interaction: Pilots who started the experiment with their menstrual day were less susceptible to the effects of alcohol during the second test day than were pilots who started with their luteal day. CONCLUSIONS: The tested menstrual cycle phases and varying E2 and P levels did not significantly influence postdrink flight performance. Because the present study included a comparatively large sample size and because it involved complex "real world" tasks (piloting an aircraft), we believe that the present findings are important. We hope that our failure to detect menstrual cycle effects will encourage researchers to include women in their investigations of alcohol effects and human performance.


Subject(s)
Aerospace Medicine , Alcohol Drinking , Cognition/physiology , Menstrual Cycle/physiology , Adult , Cognition/drug effects , Estradiol/blood , Ethanol/blood , Ethanol/pharmacology , Female , Humans , Menstrual Cycle/drug effects , Progesterone/blood , Reaction Time , Time Factors
16.
Neurology ; 56(11): 1595-7, 2001 Jun 12.
Article in English | MEDLINE | ID: mdl-11402127

ABSTRACT

The reason for differences in rate of cognitive decline in AD is unknown. The interleukin-1 alpha (IL-1 alpha) -889 *2 allele is associated with increased risk for AD. Surprisingly, in a sample of 114 patients followed for an average of 3.8 years, individuals homozygous for the IL-1 alpha -889 *1 allele declined significantly more rapidly on the Mini-Mental State Examination than did others. There was no difference in rate of decline between patients with and without the APOE epsilon 4 allele. These results support the hypothesis that inflammation is important in the clinical course of AD.


Subject(s)
Alzheimer Disease/genetics , Cognition Disorders/genetics , Interleukin-1/genetics , Adult , Aged , Aged, 80 and over , Alleles , Alzheimer Disease/immunology , Cognition Disorders/immunology , Disease Progression , Female , Genotype , Humans , Male , Polymorphism, Genetic
17.
Psychopharmacology (Berl) ; 155(2): 198-203, 2001 May.
Article in English | MEDLINE | ID: mdl-11401010

ABSTRACT

RATIONALE: Studies about whether or not the cognitive performance of women is influenced by changes in levels of sex steroid hormones across the menstrual cycle have produced ambiguous results. OBJECTIVES: This study tested whether flight simulator performance differs significantly between the menstrual and the luteal phase of the menstrual cycle. METHODS: In a within-subjects design, 24 female pilots were tested twice during their menstrual cycle: once during the menstrual and once during the luteal phase. On both test days they performed a 75-min simulator flight in a Frasca 141, a popular pilot training device. RESULTS: Despite highly significant differences in estradiol (E2) as well as progesterone (P) levels on the 2 test days, and despite excluding subjects with anovulatory cycles from the analyses, there were no significant differences in overall flight performance between the menstrual and luteal phases. We found no significant correlations between E2 or P levels and flight performance. CONCLUSIONS: We found no evidence that the tested menstrual cycle phases and their associated E2 and P levels significantly influence flight simulator performance. We consider these negative findings based on 24 subjects meaningful because previous studies on the influence of menstrual cycle on cognitive performance have not involved complex "real world" tasks such as piloting an aircraft and they obtained inconsistent results.


Subject(s)
Estradiol/metabolism , Menstrual Cycle/metabolism , Menstrual Cycle/physiology , Progesterone/metabolism , Psychomotor Performance/physiology , Adult , Central Nervous System Depressants/pharmacokinetics , Ethanol/pharmacokinetics , Female , Humans , Luteal Phase/metabolism , Luteal Phase/physiology
18.
J Int Neuropsychol Soc ; 7(3): 384-90, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11311039

ABSTRACT

This study examined the relationships between regional cortical and hippocampal brain volumes and components of remote memory (recall, recognition, sequencing, and photo naming of presidential candidates) in 13 individuals with Alzheimer's disease (AD). Recognition and sequencing of remote memory for public figures were associated with regional cortical volumes. Specifically, lower recognition and sequencing scores were associated with smaller parietal-occipital cortical volumes; poorer sequencing was also associated with smaller prefrontal cortical volumes. By contrast, poorer anterograde but not remote memory scores were correlated with smaller hippocampal volumes. Within the constraints of the brain regions measured, these findings highlight the importance of the posterior cortical areas for selective remote memory processes and provide support for the dissociation between cortically mediated remote memory and hippocampally mediated anterograde memory.


Subject(s)
Alzheimer Disease/pathology , Alzheimer Disease/psychology , Cerebral Cortex/pathology , Limbic System/pathology , Memory/physiology , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged
19.
J Exp Psychol Gen ; 130(4): 746-63, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11757878

ABSTRACT

A theory of cognitive aging is presented in which healthy older adults are hypothesized to suffer from disturbances in the processing of context that impair cognitive control function across multiple domains, including attention, inhibition, and working memory. These cognitive disturbances are postulated to be directly related to age-related decline in the function of the dopamine (DA) system in the prefrontal cortex (PFC). A connectionist computational model is described that implements specific mechanisms for the role of DA and PFC in context processing. The behavioral predictions of the model were tested in a large sample of older (N = 81) and young (N = 175) adults performing variants of a simple cognitive control task that placed differential demands on context processing. Older adults exhibited both performance decrements and, counterintuitively, performance improvements that are in close agreement with model predictions.


Subject(s)
Aging/physiology , Cognition/physiology , Dopamine/metabolism , Health Status , Prefrontal Cortex/metabolism , Psychological Theory , Adult , Aged , Aged, 80 and over , Female , Humans , Male
20.
Dialogues Clin Neurosci ; 3(3): 191-213, 2001 Sep.
Article in English | MEDLINE | ID: mdl-22033831

ABSTRACT

The United Nations projects that the number of individuals with dementia in developed countries alone will be approximately 36,7 million by the year 2050. International recognition of the significant emotional and economic burden of Alzheimer's disease has been matched by a dramatic increase in the development of pharmacological and nonpharmacological approaches to this illness in the past decade. Changing demographics have underscored the necessity to develop similar approaches for the remediation of the cognitive impairment associated with more benign syndromes, such as mild cognitive impairment (MCI) and age-associated cognitive decline (AACD). The present article aims to provide an overview of the most current therapeutic approaches to age-associated neurocognitive disorders. Additionally, it discusses the conceptual and methodological issues that surround the design, implementation, and interpretation of such approaches.

SELECTION OF CITATIONS
SEARCH DETAIL
...